N/A N=7 Opioid Taper Study
Chronic Pain
Primary: Pain Perception Measured Using the Cold-pressor Test (CPT) — 24.01; 42.02 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=237 Heritability of Opioid Effects: A Twin Study
Pain
Primary: Heat Pain Threshold — 49.6; 48.6 degrees centigrade
N/A N=56 Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea
Sleep Apnea, Obstructive
Primary: Experimental Cold-induced Pain - IGFBP-1 — 0.0025 [sec/(mcg/mL)] /pg/mL — p=<0.05
N/A N=9 Aprepitant Effects on Oxycodone Response
Narcotic Abuse
Primary: Abuse Liability Proxy — 0.197; 0.483; 0.159; 7.678 units on a scale (points 0-100) — p=<.05
N/A N=293 Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia
Labor Pain · Post-cesarean Delivery
Primary: Duration of Intrathecal Fentanyl Analgesia — 70; 63 Minutes — p=0.54
Phase 4 N=20 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold
Healthy
Primary: Hot and Cold Thermal Sensory Threshold for Pain at Baseline in Degrees Celsius. — 43.93; 43.0; 14.81; 13.33 degrees Celsius — p=.47
N/A N=93 Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function
Chronic Pain
Primary: Mean of the Change in Morphine Dosage (in mg) Required to Achieve 25% Reduction in Thermal Evoked Pain Responses Relative to Baseline (Pre-intervention) Placebo…
Phase 2 N=97 A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
Opioid Sensitivity · Individual Difference · Abuse Opioids
Primary: Self-report Visual Analog Ratings of HIGH — 7.2; 6.6; 4.5; 5.6 score on a scale — p=0.567
Phase 4 N=42 Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Depression · Insulin Resistance · Metabolic Syndrome
Primary: Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State
Phase 2 N=10 Genetic Effects on Dopamine Response to an Opiate
Polymorphism-Genetic · Pain · Addiction
Primary: 11C Raclopride Binding Potential in Caudate — 3.25; 3.45 mCi/ml
N/A N=10 Differentiating the Effects of Substance P and Beta-endorphin
Chronic Obstructive Pulmonary Disease
Primary: Unpleasantness of Breathlessness — 69.0; 71.1 units on a scale
Phase 2 N=84 Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception
Pain · Hypogonadism
Primary: Brief Pain Inventory (BPI) at Week 14 — 10.2; 9.7; 5.3; 5.1 units on a scale
Phase 2 N=10 Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
Hyperalgesia
Primary: Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH). — -28…
Phase 4 N=169 Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section
Postoperative Pain
Primary: Milligrams of Intravenous Morphine Used by Participant in First 24 Hours Postoperatively — 18; 14; 15 Milligrams
Phase 3 N=10 Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age
Opioid Toxicity · Pupillary Miosis · Respiratory Depression
Primary: Area Under the Time Concentration Curve (AUROC ) — 0.9700 Probability
N/A N=27 The Effects of Minocycline in Opioid-maintained Patients
Opioid Dependence · Pain
Primary: Pain Threshold — 18.72; 24.78; 16.16; 24.37 seconds
Phase 2 N=13 Opioid Modulation and Neural Reward Activation in Healthy Adults
Alcohol Drinking · Opioid Use, Unspecified
Primary: Change in Brain Activation to Reward Between Placebo and Active Medication — 0.25; 0.26 percentage signal change
Early Phase 1 N=28 Sensory and Opioid Mechanisms of Affective Touch
Pain · Touch
Primary: Change in Pleasantness of Skin Brushing From Before to After Infusion — -9.6875; -4.9583 Units on a scale
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 4 N=81 Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms
Chronic Low Back Pain · Degenerative Disc Disease · Depression
Primary: Percent Change in Average Daily Pain Score — 38.6; 30.0; 20.6 percent change — p=0.01
Phase 4 N=172 Opioid Analgesia for MAB
MAB · Pain
Primary: Overall Maximum Self-reported Pain Score — 8; 8 units on a scale
N/A N=94 Opioid Sparing Potential of Light-Induced Analgesia
Pain
Primary: Change in Pain Level — 1.15; -0.04; 1.07 score on a scale
N/A N=22 Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil
Hyperalgesia
Primary: Pain Tolerance — 105.3; 19.2 seconds
Phase 2 N=32 Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
N/A N=14 Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 77; 83 units on a scale — p=.0004
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
N/A N=34 Neuropharmacological Basis of Social Connection: The Role of Opioids
Psychology, Social
Primary: Changes in Self-reported Feelings of Connection During Naltrexone (vs. Placebo) — 5.92; 6.47 units on a scale
Phase 2 N=174 Association Between Body Size and Response to Hydromorphone in ED
Pain
Primary: Correlation Between Change in Pain Intensity and TBW at 30 Minutes Post-treatment — -0.03 correlation coefficient
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale